Stock Watch: GLP-1 Expectations Dashed

Pfizer’s Foray Into Obesity Slims Down As Tolerability Becomes The New Battleground

 
• By Andy Smith
  
Generate a summary of this article
Listen to this article
Beta

If oral GLP-1 agonists are going to be successful in a wider weight loss indication, lower efficacy may be the trade-off for better tolerability in this bigger and more healthy population.

Andy Smith
ANDY SMITH OFFERS A LIFE SCIENCE INVESTOR'S PERSPECTIVE ON BIOPHARMA BUSINESS

The title of a note on Pfizer Inc.* by the analysts at J.P. Morgan in late November included the question “Where Is The Bottom?” – referring to its stock price. At that time, Pfizer’s stock price had fallen in the year to the end of November by over 40%. This compared with an 11-month gain of just over 2% for the NYSE Arca Pharmaceutical Index (DRG). Among the list of Pfizer’s key pipeline assets highlighted in the note was the oral GLP-1 agonist danuglipron where the J.P. Morgan analysts saw “a favorable risk/reward into ph2 data” as Pfizer attempted to encroach on Novo Nordisk A/Ss and Eli Lilly and Company’s market for GLP-1 agonists in diabetes and obesity.

Expectations for the Phase II study of danuglipron had been running high long before the licensing of another oral GLP-1...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Stock Watch

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.